Terms ending in 2035
Bayer Pharma Aktiengesellschaft
Every in-force patent on Bayer Pharma Aktiengesellschaft's record whose computed term ends in 2035, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,951,027 | BENZIMIDAZOL-2-Amines as MIDH1 Inhibitors In force · High confidence | Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts | In force | High confidence | |
| US 10,155,950 | Immunostimulatory Plasmids In force · High confidence | Elanco Animal Health GmbH | In force | High confidence | |
| US 10,851,379 | Immunostimulatory Plasmids In force · High confidence | Elanco Animal Health GmbH | In force | High confidence | |
| US 9,771,360 | Cyano-Substituted Imidazo[1,2-a]pyridinecarboxamides and Their Use In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,046,110 | Lock for Drug Injection Device In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US RE49,575 | Method for the Preparation of (4S)-4-(4-Cyano-2-Methoxyphenyl)-5-Ethoxy-2,8-Dimethyl-1,4-Dihydro-1-6-Naphthyridine-3-Carbox-AMIDE and the Purification Thereof for Use as an Active Pharmaceutical Ingredient In force · Low confidence | Bayer Pharma Aktiengesellschaft | In force | Low confidence | |
| US RE49,826 | Method for the Preparation of (4S)-4-(4-Cyano-2-Methoxyphenyl)-5-Ethoxy-2,8-Dimethyl-1,4-Dihydro-1-6-Naphthyridine-3-Carboxamide and the Purification Thereof for Use as an Active Pharmaceutical Ingredient In force · Low confidence | Bayer Pharma Aktiengesellschaft | In force | Low confidence | |
| US RE49,860 | Process for Preparing (4S)- 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide and Purification Thereof for Use as a Pharmaceutical Active Ingredient In force · Low confidence | Bayer Pharma Aktiengesellschaft | In force | Low confidence | |
| US 9,549,932 | 2-(MORPHOLIN-4-YL)-1,7-Naphthyridines In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| US 10,729,680 | 5-Substituted 2-(MORPHOLIN-4-YL)-1,7-Naphthyridines In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | |
| 17 more term ends in 2035 · Pro | |||||
10 of 27 patents shown. Soonest term end first, then patent number.
Pro members see all 27.
18 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.